Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)

Trial Profile

A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tisagenlecleucel (Primary) ; Tocilizumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2022 Results (n=206) assessing the influence of household poverty and neighborhood social determinants on outcomes from CAR T-cell therapy for relapsed/refractory leukemia from (NCT01626495; NCT02435849 ; NCT02374333; NCT02228096; NCT02906371) clinical trials and commercial tisagenlecleucel from 2012 to 2020, published in the Blood.
    • 07 Jun 2022 Results assessing impact of socioeconomic status on survival after CD19 CART therapy using data from CD19 CART clinical trials (NCT01626495, NCT02435849, NCT02374333, NCT02228096, NCT02906371) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top